Literature DB >> 23127858

Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case.

Thierry Kogej1, Niklas Blomberg, Peter J Greasley, Stefan Mundt, Mikko J Vainio, Jens Schamberger, Georg Schmidt, Jörg Hüser.   

Abstract

In this study, the screening collections of two major pharmaceutical companies (AstraZeneca and Bayer Pharma AG) have been compared using a 2D molecular fingerprint by a nearest neighborhood approach. Results revealed a low overlap between both collections in terms of compound identity and similarity. This emphasizes the value of screening multiple compound collections to expand the chemical space that can be accessed by high-throughput screening (HTS).
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23127858     DOI： 10.1016/j.drudis.2012.10.011

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  16 in total

1.  Opening the lead generation toolbox.

Authors:  Peter B Simpson; Melvin Reichman
Journal:  Nat Rev Drug Discov       Date:  2014-01       Impact factor: 84.694

Review 2.  Chemical probes and drug leads from advances in synthetic planning and methodology.

Authors:  Christopher J Gerry; Stuart L Schreiber
Journal:  Nat Rev Drug Discov       Date:  2018-04-13       Impact factor: 84.694

3.  Assessing HTS performance using BioAssay Ontology: screening and analysis of a bacterial phospho-N-acetylmuramoyl-pentapeptide translocase campaign.

Authors:  Andreas Moberg; Linda Zander Balderud; Eva Hansson; Helen Boyd
Journal:  Assay Drug Dev Technol       Date:  2014 Nov-Dec       Impact factor: 1.738

Review 4.  Looking beyond the hype: Applied AI and machine learning in translational medicine.

Authors:  Tzen S Toh; Frank Dondelinger; Dennis Wang
Journal:  EBioMedicine       Date:  2019-08-26       Impact factor: 8.143

5.  Impact of a five-dimensional framework on R&D productivity at AstraZeneca.

Authors:  Paul Morgan; Dean G Brown; Simon Lennard; Mark J Anderton; J Carl Barrett; Ulf Eriksson; Mark Fidock; Bengt Hamrén; Anthony Johnson; Ruth E March; James Matcham; Jerome Mettetal; David J Nicholls; Stefan Platz; Steve Rees; Michael A Snowden; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2018-01-19       Impact factor: 84.694

Review 6.  Collaborative drug discovery for More Medicines for Tuberculosis (MM4TB).

Authors:  Sean Ekins; Anna Coulon Spektor; Alex M Clark; Krishna Dole; Barry A Bunin
Journal:  Drug Discov Today       Date:  2016-11-22       Impact factor: 7.851

Review 7.  Using cultured endothelial cells to study endothelial barrier dysfunction: Challenges and opportunities.

Authors:  Jurjan Aman; Ester M Weijers; Geerten P van Nieuw Amerongen; Asrar B Malik; Victor W M van Hinsbergh
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-06-24       Impact factor: 5.464

8.  Bigger data, collaborative tools and the future of predictive drug discovery.

Authors:  Sean Ekins; Alex M Clark; S Joshua Swamidass; Nadia Litterman; Antony J Williams
Journal:  J Comput Aided Mol Des       Date:  2014-06-19       Impact factor: 3.686

9.  Collaborative virtual screening to elaborate an imidazo[1,2-a]pyridine hit series for visceral leishmaniasis.

Authors:  Yuichiro Akao; Stacie Canan; Yafeng Cao; Kevin Condroski; Ola Engkvist; Sachiko Itono; Rina Kaki; Chiaki Kimura; Thierry Kogej; Kazuya Nagaoka; Akira Naito; Hiromi Nakai; Garry Pairaudeau; Constantin Radu; Ieuan Roberts; Mitsuyuki Shimada; David Shum; Nao-Aki Watanabe; Huanxu Xie; Shuji Yonezawa; Osamu Yoshida; Ryu Yoshida; Charles Mowbray; Benjamin Perry
Journal:  RSC Med Chem       Date:  2021-01-21

10.  BIGCHEM: Challenges and Opportunities for Big Data Analysis in Chemistry.

Authors:  Igor V Tetko; Ola Engkvist; Uwe Koch; Jean-Louis Reymond; Hongming Chen
Journal:  Mol Inform       Date:  2016-07-28       Impact factor: 3.353
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.